LADARIXIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C11H12F3NO6S2
Molecular Weight	375.341
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@@H](C(=O)NS(C)(=O)=O)C1=CC=C(OS(=O)(=O)C(F)(F)F)C=C1

InChI

InChIKey=DDLPYOCJHQSVSZ-SSDOTTSWSA-N

InChI=1S/C11H12F3NO6S2/c1-7(10(16)15-22(2,17)18)8-3-5-9(6-4-8)21-23(19,20)11(12,13)14/h3-7H,1-2H3,(H,15,16)/t7-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C11H12F3NO6S2
Molecular Weight	375.341
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/mesh/67511776 | https://www.ncbi.nlm.nih.gov/pubmed/16613761 | https://www.ncbi.nlm.nih.gov/pubmed/28129639

LADARIXIN is a dual inhibitor of chemokine receptors CXCR1 and CXCR2. It inhibits human polymorphonuclear leukocyte (PMN) migration to chemokine CXCL8 in vitro and prevents PMN infiltration and tissue damage in several models of cerebral ischemia/reperfusion in vivo. It is under development for the treatment of type 1 diabetes.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
C-X-C chemokine receptor type 1 1 Target ID: P25024\|\|\|Q6IN95 Gene ID: 3577.0 Gene Symbol: CXCR1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/21718305 \| https://www.ncbi.nlm.nih.gov/pubmed/16613761	Antagonist 2778
C-X-C chemokine receptor type 2 2 Target ID: P25025 Gene ID: 3579.0 Gene Symbol: CXCR2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/21718305 \| https://www.ncbi.nlm.nih.gov/pubmed/16613761	Antagonist 2778

PubMed

Title	Date	PubMed
Predicting human serum albumin affinity of interleukin-8 (CXCL8) inhibitors by 3D-QSPR approach.	2005 Apr 7	15801837
Development of a systemically-active dual CXCR1/CXCR2 allosteric inhibitor and its efficacy in a model of transient cerebral ischemia in the rat.	2006 Mar	16613761
Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2.	2007 Aug 23	17665889
Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non-competitive allosteric inhibitor.	2012 Jan	21718305
Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment.	2017 Feb 28	28129639

Substance Class	Chemical Created by `admin` on `Fri Dec 15 22:10:38 GMT 2023` Edited by `admin` on `Fri Dec 15 22:10:38 GMT 2023`
Record UNII	DEH7Q6472O
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LADARIXIN

Official Name

English

METHANESULFONIC ACID, 1,1,1-TRIFLUORO-, 4-((1R)-1-METHYL-2-((METHYLSULFONYL)AMINO)-2-OXOETHYL)PHENYL ESTER

Common Name

English

METHANESULFONIC ACID, TRIFLUORO-, 4-((1R)-1-METHYL-2-((METHYLSULFONYL)AMINO)-2-OXOETHYL)PHENYL ESTER

Common Name

English

(R)-(-)-N-(2-(4-(TRIFLUOROMETHANESULFONYLOXY)PHENYL)PROPIONYL)METHANESULFONAMIDE

Systematic Name

English

ladarixin [INN]

Common Name

English

Ladarixin [WHO-DD]

Common Name

English

4-((2R)-1-OXO-1-(METHANESULFONAMIDO)PROPAN-2-YL)PHENYL TRIFLUOROMETHANESULFONATE

Systematic Name

English

Code System Code Type Description

NCI_THESAURUS

C170087